Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 51 for “"trastuzumab"”.
-
Identification of Markers to Predict Benefit from Trastuzumab Treatment
Despite the clinical benefit of trastuzumab, some patients do not respond to this therapy. Aims of this study are to identify new predictive biomarkers to distinguish responsive from <i>de novo</i> resistant tumours and to have new insights into the biological characterisation of trastuzumab …
-
Enhertu (Trastuzumab Deruxtecan): Ανασκόπηση της κλινικής ανάπτυξης σε ασθενείς με HER2+ καρκίνο μαστού / Enhertu (Trastuzumab Deruxtecan): A review of clinical development in patients with HER2-positive breast cancer
… ρόλου της τραστουζουμάμπης δερουξτεκάνης (Trastuzumab Deruxtecan, T-DXd, Enhertu) σε ασθενείς με HER2-θετικό καρκίνο του μαστού, εστιάζοντας στην αποτελεσματικότητα, την ασφάλεια και τον ρόλο της στα σύγχρονα θεραπευτικά σχήματα. Μεθοδολογία: Πραγματοποιήθηκε συστηματική αναζήτηση στη …
-
Jab1 Negatively Regulates Pten and Promotes Resistance to Trastuzumab In Her2-Positive Breast Cancer
… approximately 20% of all breast cancer cases. Trastuzumab (Herceptin), the first targeted therapy approved for HER2-positive disease, potently prevents the activation of signaling pathways downstream of HER2 and significantly improves patients’ outcomes. However, resistance to trastuzumab is …
-
Mdm2-Mediated Degradation of Sirt6 Phosphorylated By Akt1 Promotes Tumorigenesis and Trastuzumab Resistance In Breast Cancer
… vivo.</em> In addition, knockdown of SIRT6 in trastuzumab-sensitive cells renders them resistant to trastuzumab whereas overexpression of phosphorylation defective SIRT6 mutant restores trastuzumab sensitivity in the resistant cells. Thus, activation or re-expression of SIRT6 has potential …
-
The role of receptor tyrosine kinase signalling in HER-2-positive cells and trastuzumab (Herceptin) resistance in breast cancer
… in approximately 25 % of breast cancers, and trastuzumab (Tmab) is a monoclonal antibody currently used to treat patients with HER-2-overexpressing breast cancer. Signalling through alternative receptor tyrosine kinases, such as insulin-like growth factor I receptor (IGF-IR), has been …
-
INVESTIGATION OF LIGAND SIZE ON TARGETED PLGA NANOPARTICLES FOR HER2 BREAST CANCER: TRASTUZUMAB AND ITS ScFv ANTI-HER2 ANTIBODY
This research focuses on assessing the effect of various formulation parameters on targeting human epidermal growth factor receptor-2 (HER2) specifically in breast cancer. Poly (D, L-lactide-co-glycolide) (PLGA) polymer, which is approved by FDA, was used to form nanoparticles (NPs) encapsulating …
-
Pathological response of breast cancer to neo-adjuvant chemotherapy at a single tertiary centre with no access to Trastuzumab
… a combined approach involving chemotherapy and Trastuzumab for individuals with HER2-positive breast cancer, Groote Schuur Hospital faces constraints in administering Trastuzumab due to cost-related considerations. This study delves into the impact of neoadjuvant chemotherapy on breast cancer …
-
Development and Evaluation of Novel Anti-HER2 Theranostics Against HER2-Positive Breast Cancer
… and approval of anti-HER2 monoclonal antibody trastuzumab which is now the standard of care treatment. However, the disease relapses in almost all patients. As a result, alternative HER2-targeted therapies, such as pertuzumab, margetuximab, T-DM1, T-DXd, lapatinib, neratinib, pyrotinib, …
-
Novel Role of ErbB-2 in Inhibition of Jagged-1-Mediated Trans-Activation of Notch in Breast Cancer
… the treatment of ErbB-2 positive breast cancer: trastuzumab, a humanized monoclonal antibody is directed against the extracellular domain of ErbB-2 and lapatinib, a dual EGFR/ErbB-2 tyrosine kinase inhibitor. Unfortunately, anti-ErbB-2 therapy resistance remains a major problem in metastatic …
-
Perfil de utilização do trastuzumabe no tratamento do câncer de mama
Trastuzumab is a biological drug incorporated into the Brazilian Unified Health System (SUS, in Portuguese) in 2013 to treat non-metastatic breast cancer with over expression of HER2. The aim of this study was to evaluate the diffusion and patterns of use of trastuzumab in the treatment of …
-
Targeting the actin cytoskeleton in HER2+ metastatic cancer cells using a macrolide toxin
… HER2+ cancers have been effectively targeted by Trastuzumab and Trastuzumab-based ADCs, we tested the effects of a combination of Trastuzumab and MycB on cell migration and invasion. We found that MycB/ Trastuzumab combination treatments inhibited motility of SKOV3 cells to a greater degree than …
-
Engineering therapeutic messenger RNA for triple-negative breast cancer
… oncology. The HER2-targeting monoclonal antibody trastuzumab has dramatically improved the survival of patients with HER2-positive breast cancer. More recently developed antibody-drug conjugates, such as trastuzumab deruxtecan (T-DXd), have demonstrated unprecedented efficacy in …
-
Role of X-Linked Inhibitor of Apoptosis Protein in Therapeutic Resistance of Inflammatory Breast Cancer Cells
… ErbB-targeting is clinically relevant using trastuzumab (anti-ErbB2 antibody) and lapatinib (small molecule ErbB1/2 inhibitor). However, acquired resistance is a common outcome even in IBC patients who show an initial clinical response, which limits the efficacy of these agents. Little is …
-
Role Of d16HER2 Splice Variant In Breast Cancer Stem Cells
… activation determines the greatest benefits from trastuzumab administration in HER2+ BCs. Additionally, our results pointed to a crucial d16HER2 role in the regulation of the BC stem cells (BCSCs) activity through its functional interaction with the NOTCH family members. We also observed that the …
-
Studio di nuovi approcci farmacologici in grado di inibire l'attivazione dei recettori del fattore di crescita epidermico (EGF) in linee cellulari di carcinoma polmonare non a piccole cellule (NSCLC)
… anticorpo monoclonale diretto contro l'EGFR e trastuzumab, anticorpo monoclonale diretto contro l'HER-2, a diverse concentrazioni per 72 h. Mediante il saggio di proliferazione MTT (3,(4,5-dimethylthiazol-2)2,5 difeniltetrazolium bromide) è stato osservato il 91,4% di inibizione della …
-
Prevention of cancer therapy related cardiotoxicity: A Tayside Pharmaco-Epidemiology study (PROTECT-TAYSIDE study)
… may cause irreversible cardiotoxicity, though trastuzumab-induced damage can be reversed upon stopping. Various animal studies have shown that cardioprotective drugs such as ACE inhibitors, Beta-blockers and statins can reduce pathological processes such as oxidative stress as a result of …
-
Data Mining for Signal Detection of Targeted Therapy Related Drug Toxicity in Breast Cancer Patients
… chemotherapy and 2,542 patients treated with trastuzumab in addition to chemotherapy. Inpatient and outpatient visits up to 1 year from start of therapy were used to identify adverse events (AEs). For each method two signaling thresholds were evaluated. Across all methods we found a total of …
-
Data Mining for Signal Detection of Targeted Therapy Related Drug Toxicity in Breast Cancer Patients
… chemotherapy and 2,542 patients treated with trastuzumab in addition to chemotherapy. Inpatient and outpatient visits up to 1 year from start of therapy were used to identify adverse events (AEs). For each method two signaling thresholds were evaluated. Across all methods we found a total of …
-
Treatment outcomes of Her-2 positive Breast Cancer in the absence of Her-2 targeting agents at Groote Schuur Hospital, Cape Town, South Africa. Are we doing enough?
… The addition of anti- Her-2 targeted therapy (Trastuzumab) to either adjuvant or neo-adjuvant treatment significantly improves disease-free survival and overall survival of women with early-stage Her-2 positive breast cancer. However, at Groote Schuur Hospital anti-Her-2 targeted treatment is …
Page 1 of 3